Pacer US Small Cap Cash Cows Growth Leaders Etf(CAFG.US)

Company Encyclopedia
View More
name
Pacer US Small Cap Cash Cows Growth Leaders Etf
CAFG.US
News
View More

Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path

Krystal Biotech (NASDAQ:KRYS) announced positive interim results for its inhaled cystic fibrosis gene therapy candidate KB407, confirming wild-type CFTR protein expression in patients' lungs. The company plans to initiate repeat dosing and potentially move towards a registrational study. CEO Krish Krishnan highlighted the breakthrough in CFTR delivery, while Dr. Jorge Lascano noted that some patients do not benefit from existing CFTR modulators. The Phase 1 CORAL-1 study is evaluating the safety and efficacy of KB407, with promising results in patient biopsies showing CFTR expression.

Market Beat·
US
KRYS
+1.03%
Market Beat·
US
KRYS
+1.03%

Krystal Biotech Reports Positive Interim Results for KB407 in Cystic Fibrosis Trial

Krystal Biotech Inc. reported positive interim results from its Phase 1 CORAL-1 study of KB407 for cystic fibrosis, showing successful delivery of CFTR protein in airway cells. Transduction rates ranged from 29.4% to 42.1%. The treatment was well tolerated, with mostly mild adverse events. The company has submitted a design for a follow-up study, CORAL-3, to the FDA, with enrollment expected in the first half of 2026. Further details will be shared at study initiation.

Reuters·
US
KRYS
+1.03%
Reuters·
US
KRYS
+1.03%

DigitalOcean (DOCN) expands AI partnerships as demand for agentic cloud rises

DigitalOcean Holdings, Inc. (NYSE:DOCN) has expanded its AI partnerships amid rising demand for agentic cloud services. The company reported impressive third-quarter earnings, with revenues of $230 million, a 16% increase year-over-year, and net income of $158 million, up 381% year-over-year. Additionally, DigitalOcean has a positive growth outlook for the full year 2025, making it one of the best AI stocks to buy under $50.

MSN·
US
DOCN
-2.04%
MSN·
US
DOCN
-2.04%

Vicor CFO James F. Schmidt Reports Sale of Common Shares

James F. Schmidt, CFO of Vicor Corporation, reported the sale of common shares of the company. This information was published via EDGAR by the U.S. SEC on December 23, 2025. The news is generated by Public Technologies using AI and is for informational purposes only.

Reuters·
US
VICR
-2.41%
Reuters·
US
VICR
-2.41%

PTC Therapeutics Wins Japan Approval for Sephience to Treat PKU

PTC Therapeutics Inc. has received approval from Japan's Ministry of Health for Sephience™ to treat phenylketonuria (PKU) in all age groups. This marks PTC's first product approval in Japan. Pricing discussions are expected to conclude by Q1 2026, followed by the product launch. The news was originally published by PTC via PR Newswire on December 22, 2025.

Reuters·
US
PTCT
-0.50%
Reuters·
US
PTCT
-0.50%
© 2026 Longbridge｜Disclaimer